- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02583269
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Muscadine Grape Extract (MGE) in Advanced Malignancy
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the safety and maximum tolerated dose (MTD) of MGE (muscadine grape skin extract) after 4 weeks of administration for patients with metastatic cancer.
Secondary Objectives:
I. To monitor adverse events/toxicity every 4 weeks while on treatment. II. To evaluate change in phenolic levels (total and component, blood and urine) from baseline to 4 and 8 weeks.
III. To evaluate change in serum cytokines and growth factors from baseline to 4 and 8 weeks on MGE.
IV. To observe the response rate of MGE in patients with metastatic cancer. V. To assess overall and progression-free survival in patients with metastatic cancer receiving MGE.
VI. To assess global quality of life (Functional Assessment of Cancer Therapy-General [FACT-G] and fatigue (Patient Reported Outcomes Measurement Information System [PROMIS]-fatigue Short Form [SF]) in cancer patients taking MGE.
VII. To assess adherence to MGE treatment.
OUTLINE: This is a dose-escalation study.
Patients receive muscadine grape skin extract orally (PO) twice daily (BID). Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days and then every 6 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is metastatic or unresectable and have failed standard therapies
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Absolute neutrophil count >= 1000/mcL
- Platelets >= 50,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit or normal
- Creatinine clearance >= 40 mL/min
- Stable supplement usage for > 2 weeks prior to starting and agrees not to change while on this study
- Life expectancy > 3 months
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients may not be receiving any other investigational cancer-directed agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to MGE
- Patients unable to take oral medications or those with history of malabsorption due to bowel resection
- Patients with uncontrolled diarrhea or persistent nausea/vomiting requiring daily antiemetic therapy for symptom management
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued
- Patients with primary brain tumors are excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 (muscadine grape skin extract) 1 pill 2 times a day
Patients receive muscadine grape skin extract PO BID.
Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity.
Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Other Names:
Correlative studies
Given PO
Other Names:
|
Experimental: Arm 2 (muscadine grape skin extract) 2 pills 2 times a day
Patients receive muscadine grape skin extract PO BID.
Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity.
Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Other Names:
Correlative studies
Given PO
Other Names:
|
Experimental: Arm 3 (muscadine grape skin extract) 3 pills 2 times a day
Patients receive muscadine grape skin extract PO BID.
Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity.
Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Other Names:
Correlative studies
Given PO
Other Names:
|
Experimental: Arm 4 (muscadine grape skin extract) 4 pills 2 times a day
Patients receive muscadine grape skin extract PO BID.
Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity.
Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Other Names:
Correlative studies
Given PO
Other Names:
|
Experimental: Arm 5 muscadine grape skin extract) 5 pills 2 times a day
Patients receive muscadine grape skin extract PO BID.
Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity.
Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Other Names:
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose-Limiting Toxicity
Time Frame: 29 days
|
Maximum tolerable dose of muscadine grape extract is defined as the dose level immediately below the dose level that induced a dose-limiting toxicity (DLT) in >= 2 patients, as assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0DLT will be assessed by severity of adverse events.
|
29 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to MGE Treatment, as Measured by Percent of Pills Taken at the End of Every 4 Week Period
Time Frame: Up to 1 year
|
Pill count will be calculated from counting the number of pills returned as well as by summarizing the patient's pill diary.
The percent of pills taken will be summarized by dose level using the median and 95% confidence interval.
Investigators will summarize the percent of pills taken at the end of every 4 week period i using the formula: Percent of pills taken)i = (Dose Level ×7 ×4)i minus Pill Count divided by Dose Level ×7 ×4)i
|
Up to 1 year
|
Best Response
Time Frame: At the end of treatment, up to 1 year
|
Best response will be characterized using a frequency table.
Evaluation of new or enlarging effusions to differentiate between Progressive Disease and Response/Stable Disease.
Measurements will be obtained from usual care imaging and assessed by the principal investigators in confirmation with the physician of record.
Clinical lesions will only be considered measurable when they are superficial and ≥10 mm in diameter as assessed using calipers.
For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.
|
At the end of treatment, up to 1 year
|
Change in Total Phenolic Levels in Blood
Time Frame: Baseline to up to 8 weeks
|
A mixed model analysis of variance (ANOVA) model will be fit with phenolic level as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Change in Total Phenolic Levels in Urine
Time Frame: Baseline to up to 8 weeks
|
A mixed model analysis of variance (ANOVA) model will be fit with phenolic level as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Change in Quality of Life and Fatigue in Cancer Patients Taking MGE as Measured by FACT-G
Time Frame: Baseline to up to 1 year
|
A mixed model ANOVA model will be fit with phenolic level as the outcome and time (baseline, every 4 weeks) as a fixed effect and subject as a random effect.
Contrasts will be use to estimate changes from baseline to each follow-up time period.
Score scales from 0 (not at all) to 4 (very much).
Sum of scores range 0-28 for social, functional and physical well being and 0-24 for emotional well being and multiplied by 6.
All four scores are totaled with a score range of 0-108.
A mean of the combined group scores will be used.
A higher score indicates a higher worse outcome of the illness on the participant.
|
Baseline to up to 1 year
|
Change in Systemic Cytokine Levels
Time Frame: Baseline to up to 8 weeks
|
A mixed model ANOVA model will fit with the outcome of interest (cytokine or growth factor) as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Incidence of Adverse Events (AEs), Assessed Using NCI CTCAE Version 4.0
Time Frame: Up to 1 year
|
AEs/toxicity will be assessed at weeks 4, 8 and every 4 weeks thereafter if patients remain on treatment.
Any expected toxicities, any laboratory based toxicities, and any grade 3 or higher gastrointestinal toxicities, and any grade 4 or higher toxicities will be summarized using frequency tables overall and by week.
|
Up to 1 year
|
Overall Response Rate of MGE (Complete Response, Partial Response, and Stable Disease)
Time Frame: At 8 weeks
|
Response will be characterized using a frequency table.
|
At 8 weeks
|
Overall Survival (OS)
Time Frame: Up to 4 years
|
OS will summarized using the Kaplan-Meier method.
Median survival rates and associated 95% confidence intervals will be calculated.
|
Up to 4 years
|
Progression-free Survival (PFS)
Time Frame: Up to 4 years
|
PFS will summarized using the Kaplan-Meier method.
|
Up to 4 years
|
Change in Component Phenolic Levels in Urine
Time Frame: Baseline to up to 8 weeks
|
A mixed model analysis of variance (ANOVA) model will be fit with phenolic level as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Change in Component Phenolic Levels in Blood
Time Frame: Baseline to up to 8 weeks
|
A mixed model analysis of variance (ANOVA) model will be fit with phenolic level as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Change in Quality of Life and Fatigue in Cancer Patients Taking MGE as Measured by PROMIS-Fatigue SF
Time Frame: Baseline to up to 1 year
|
A mixed model ANOVA model will be fit with phenolic level as the outcome and time (baseline, every 4 weeks) as a fixed effect and subject as a random effect.
Contrasts will be use to estimate changes from baseline to each follow-up time period.
A 6-item questionnaire with T-score responses ranging from a minimum of 33.4 to a maximum of 76.8.
Higher scores equals more of the concept being measured.
|
Baseline to up to 1 year
|
Change in Systemic Cytokine Levels (Log IL-8)
Time Frame: Baseline to up to 8 weeks
|
A mixed model ANOVA model will fit with the outcome of interest (cytokine or growth factor) as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Change in Systemic Cytokine Levels (Log VEGF)
Time Frame: Baseline to up to 8 weeks
|
A mixed model ANOVA model will fit with the outcome of interest (cytokine or growth factor) as the outcome and time (baseline, 4, and 8 weeks) as a fixed effect and subject as a random effect.
Contrasts will be used to estimate the changes from baseline to week 4 and week 8.
|
Baseline to up to 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Heidi Klepin, Wake Forest University Health Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00035394
- P30CA012197 (U.S. NIH Grant/Contract)
- NCI-2015-01710 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CCCWFU 01815 (Other Identifier: Wake Forest University Health Sciences)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Malignant Neoplasm
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnLocally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States